NEJM:来曲唑、促性腺激素、或克罗米芬治疗原因不明的不孕不育

2015-09-24 崔倩 译 MedSci原创

对于不明原因的不孕女性患者的标准治疗是促性腺激素或克罗米芬。使用来曲唑刺激卵巢已经被建议用来保持出生率的同时也减少多胎妊娠。在一项多中心,随机试验中,研究人员招募了有不明原因不孕不育的夫妇。18〜40岁的排卵并且至少一个专利输卵管的女性被随机分配到使用促性腺激素进行卵巢刺激(最多四个周期)组(301名女性),克罗米酚组(300名女性),或来曲唑组(299名女性)。主要成果是临床妊娠女性中多胎妊娠率

对于不明原因的不孕女性患者的标准治疗是促性腺激素或克罗米芬。使用来曲唑刺激卵巢已经被建议用来保持出生率的同时减少多胎妊娠。

在一项多中心的随机试验中,研究人员招募了有不明原因不孕不育的夫妇。18〜40岁的排卵并且至少一个再通输卵管的女性被随机分配到使用促性腺激素进行卵巢刺激(最多四个周期)组(301名女性)、克罗米芬组(300名女性)、或来曲唑组(299名女性)。主要成果是临床妊娠女性中多胎妊娠率。

促性腺激素、克罗米芬、或来曲唑进行临床治疗后,临床妊娠发生率分别为35.5%,28.3%,和22.4%,婴儿出生率分别为32.2%,23.3%和18.7%;使用来曲唑治疗的妊娠率比标准治疗(促性腺激素或克罗米芬)(P=0.003)或单独促性腺激素(P <0.001)要低,但不比单独克罗米芬治疗的妊娠率低(P=0.10)。在有胎儿心脏活动的妊娠中,使用来曲唑的多胎妊娠率(67例妊娠中的9例,13%)与促性腺激素或克罗米芬(42/192,22%;P=0.15)或克罗米芬单独治疗(8/85,9%,P=0.44)没有显著不同,但比单独促性腺激素治疗的多胎妊娠率低(34/107,32%;P=0.006)。在克罗米芬和来曲唑组所有的多胎妊娠都是双胞胎,而促性腺激素治疗则出现24例双胎妊娠和10例三胎妊娠。先天性异常或重大胎儿和新生儿并发症的发生频率在组间无显著差异。

在不明原因的不孕不育女性中,不与克罗米芬治疗比较,仅与促性腺激素治疗相比,使用来曲唑刺激排卵会显著降低多胎妊娠的频率,也会降低活产。

原始出处:

Michael P. Diamond, Richard S. Legro,Christos Coutifaris,et al.Letrozole,Gonadotropin,or Clomiphene for Unexplained Infertility,NEJM,2015.9.24

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2060702, encodeId=771c2060e022c, content=<a href='/topic/show?id=48522e070f0' target=_blank style='color:#2F92EE;'>#促性腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27070, encryptionId=48522e070f0, topicName=促性腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Wed Jun 22 05:47:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64931, encodeId=6b38649317f, content=内容再多点就更好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhRUzmFEmHvdIaOns4DmF3BicVffXjkOjBTiaMUIA4o7feGvE5IJ0SfSco4ib955Rx7bvWlib7j9V15xp/0, createdBy=814d1631326, createdName=cmn, createdTime=Sat Feb 20 16:22:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340404, encodeId=9a8a1340404ce, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61557, encryptionId=b02b6155ec9, topicName=来曲唑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Sep 26 01:47:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355070, encodeId=c0bf13550e0d0, content=<a href='/topic/show?id=b9e02036159' target=_blank style='color:#2F92EE;'>#不孕不育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20361, encryptionId=b9e02036159, topicName=不孕不育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Sep 26 01:47:00 CST 2015, time=2015-09-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2060702, encodeId=771c2060e022c, content=<a href='/topic/show?id=48522e070f0' target=_blank style='color:#2F92EE;'>#促性腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27070, encryptionId=48522e070f0, topicName=促性腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Wed Jun 22 05:47:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64931, encodeId=6b38649317f, content=内容再多点就更好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhRUzmFEmHvdIaOns4DmF3BicVffXjkOjBTiaMUIA4o7feGvE5IJ0SfSco4ib955Rx7bvWlib7j9V15xp/0, createdBy=814d1631326, createdName=cmn, createdTime=Sat Feb 20 16:22:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340404, encodeId=9a8a1340404ce, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61557, encryptionId=b02b6155ec9, topicName=来曲唑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Sep 26 01:47:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355070, encodeId=c0bf13550e0d0, content=<a href='/topic/show?id=b9e02036159' target=_blank style='color:#2F92EE;'>#不孕不育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20361, encryptionId=b9e02036159, topicName=不孕不育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Sep 26 01:47:00 CST 2015, time=2015-09-26, status=1, ipAttribution=)]
    2016-02-20 cmn

    内容再多点就更好了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2060702, encodeId=771c2060e022c, content=<a href='/topic/show?id=48522e070f0' target=_blank style='color:#2F92EE;'>#促性腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27070, encryptionId=48522e070f0, topicName=促性腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Wed Jun 22 05:47:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64931, encodeId=6b38649317f, content=内容再多点就更好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhRUzmFEmHvdIaOns4DmF3BicVffXjkOjBTiaMUIA4o7feGvE5IJ0SfSco4ib955Rx7bvWlib7j9V15xp/0, createdBy=814d1631326, createdName=cmn, createdTime=Sat Feb 20 16:22:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340404, encodeId=9a8a1340404ce, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61557, encryptionId=b02b6155ec9, topicName=来曲唑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Sep 26 01:47:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355070, encodeId=c0bf13550e0d0, content=<a href='/topic/show?id=b9e02036159' target=_blank style='color:#2F92EE;'>#不孕不育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20361, encryptionId=b9e02036159, topicName=不孕不育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Sep 26 01:47:00 CST 2015, time=2015-09-26, status=1, ipAttribution=)]
    2015-09-26 siiner
  4. [GetPortalCommentsPageByObjectIdResponse(id=2060702, encodeId=771c2060e022c, content=<a href='/topic/show?id=48522e070f0' target=_blank style='color:#2F92EE;'>#促性腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27070, encryptionId=48522e070f0, topicName=促性腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Wed Jun 22 05:47:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64931, encodeId=6b38649317f, content=内容再多点就更好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhRUzmFEmHvdIaOns4DmF3BicVffXjkOjBTiaMUIA4o7feGvE5IJ0SfSco4ib955Rx7bvWlib7j9V15xp/0, createdBy=814d1631326, createdName=cmn, createdTime=Sat Feb 20 16:22:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340404, encodeId=9a8a1340404ce, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61557, encryptionId=b02b6155ec9, topicName=来曲唑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Sep 26 01:47:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355070, encodeId=c0bf13550e0d0, content=<a href='/topic/show?id=b9e02036159' target=_blank style='color:#2F92EE;'>#不孕不育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20361, encryptionId=b9e02036159, topicName=不孕不育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Sep 26 01:47:00 CST 2015, time=2015-09-26, status=1, ipAttribution=)]

相关资讯

JCO:来曲唑联合buparlisib治疗乳腺癌安全可靠

Buparlisib是一种可逆的抑制所有 I 类磷酸肌醇-3-激酶(PIK3)的口服药物,它无论在单独或联合内分泌治疗雌激素受体阳性乳腺癌细胞株还是在异种移植中都显示出了抗肿瘤活性。这项Ib期研究评估了Buparlisib联合来曲唑在治疗ER阳性、内分泌无反应型、转移性乳腺癌中的安全性、耐受性及初步的抗肿瘤活性。【原文下载】 美国那什维尔Vanderbilt大学医学院的Ingrid A. M

招募患者:Palbociclib联合来曲唑治疗亚洲女性绝经后晚期乳腺癌的III期临床研究

1.  试验药物简介 Palbociclib(IBRANCE®)是口服、靶向性制剂,能够选择性抑制细胞周期蛋白依赖性激酶4和6(CDK4/6),恢复细胞周期控制,阻断肿瘤细胞增殖。FDA于2013年4月授予palbociclib治疗晚期或转移性ER+/HER2-乳腺癌的突破性疗法认定。 2014年研究数据表明,与标准治疗药物曲唑(letrozole)治疗组相比,palbociclib

NEJM:来曲唑更能提高多囊卵巢综合症患者的生育能力

多囊卵巢综合症(PCOS)的病因病理比较复杂,一直以来是研究和医疗领域的一大难题。日前宾州州立大学医学院的科学家领导研究团队,比较了来曲唑(letrozole)和克罗米芬(Clomiphine citrate)对PCOS的治疗作用。研究显示来曲唑更能提高PCOS患者的生育能力。据统计,有5%-10%的育龄妇女受到PCOS的困扰,这种疾病是女性不孕最常见的原因。PCOS是一种以慢性无排卵、闭经或月经

JCO:不同亚型乳腺癌,使用来曲唑效果不同

浸润性小叶癌(ILC)是第二常见的乳腺癌亚型,大约有10%的乳腺癌是这一亚型。ILC在流行病学、临床病理学特征以及对全身性治疗的响应不同于最常见的亚型浸润性导管癌(IDC)。回顾性研究表明早期ILC对于化疗的响应差于IDC。比较ILC和IDC激素疗法的有效性的资料较少。目前仍不清楚不同的疗法对于不同的亚型是不是有差异。为了评估来曲唑用于IDC或ILC相对于他莫西芬的相对效力。研究人员进行了临床试验